Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ponatinib versus Imatinib in Newly Diagnosed Chronic-Phase CML
2012-001355-38Phase 3Terminated
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ponatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Major molecular response at 12 months. Started Jul 2012; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-001355-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001355-38.